Primary sclerosing cholangitis
MONDO:0013433Primary sclerosing cholangitis (PSC) is a rare, slowly progressive liver disease characterized by inflammation and destruction of the intra- and/or extra-hepatic bile ducts that lead to cholestasis, liver fibrosis, liver cirrhosis and ultimately liver failure.
Also known as: PSC, cholangitis, primary sclerosing
52 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New antibody aims to tame rare liver disease
Disease control CompletedThis trial tests an experimental antibody drug called CM-101 in adults with primary sclerosing cholangitis (PSC), a rare liver disease. The drug targets a protein called CCL24 to potentially reduce inflammation and scarring. Participants receive either CM-101 or a placebo by intr…
Phase: PHASE2 • Sponsor: ChemomAb Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a common arthritis drug help PSC patients?
Disease control CompletedThis study tested whether sulfasalazine, a drug used for arthritis, can improve liver health and symptoms in people with primary sclerosing cholangitis (PSC) who also have inflammatory bowel disease. 32 adults across the US took either the drug or a placebo for a set time. Resear…
Phase: PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug aimed at slowing liver damage in rare bile duct disease
Disease control CompletedThis Phase 2a trial tested an experimental oral drug called PLN-74809 in 121 adults with primary sclerosing cholangitis (PSC) and suspected liver fibrosis. The main goals were to check the drug's safety and how it moves through the body. Participants received either the drug or a…
Phase: PHASE2 • Sponsor: Pliant Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New nanoparticle therapy tested for autoimmune liver disease – first human trial complete
Disease control CompletedThis first-in-human study tested a single dose of PVT201, a nanoparticle-based drug, in 24 people: healthy volunteers and patients with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC). The main goal was to check safety and how the drug moves through the …
Phase: PHASE1 • Sponsor: Parvus Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New pill shows promise for rare liver disease
Disease control CompletedThis study tested a drug called HTD1801 in 59 adults with primary sclerosing cholangitis (PSC), a rare liver disease. Participants took either a low dose, a high dose, or a placebo for 18 weeks. The main goal was to see if the drug could lower a liver enzyme called ALP, which is …
Phase: PHASE2 • Sponsor: HighTide Biopharma Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New imaging tool aims to sharpen bile duct diagnosis
Diagnosis CompletedThis completed study tested a device called NvisionVLE® that helps doctors see bile duct details during a procedure called ERCP. Only 3 adults who had the procedure between 2017 and 2019 took part. The goal was to check if the device is safe and can better find abnormalities to g…
Sponsor: Methodist Health System • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
New MRI scan could replace liver biopsies
Diagnosis CompletedThis study tested how well a special MRI scan called LiverMultiScan can measure liver fat, iron, and scarring. 61 adults with various liver diseases had up to 6 scans on different machines. The goal was to see if the results are consistent when repeated on the same scanner or on …
Sponsor: Perspectum • Aim: Diagnosis
Last updated Jun 27, 2026 08:00 UTC
-
Could a new molecule tame a rare liver disease? early safety trial begins
Knowledge-focused CompletedThis early-stage trial tests whether a single dose of HTD1801, an experimental drug for primary sclerosing cholangitis, is safe and tolerable in healthy adults. Researchers will monitor participants for side effects and measure how the drug moves through the body. The goal is to …
Phase: PHASE1 • Sponsor: HighTide Therapeutics (Hong Kong) Limited • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Can a special diet help PSC patients? small study tests two options
Knowledge-focused CompletedThis pilot study looked at how two different diets affect people with primary sclerosing cholangitis (PSC), a rare liver disease. Twenty adults were randomly assigned to either a vegan/low-sulfur diet or the specific carbohydrate diet for 8 weeks, with support from dietitians. Th…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Disposable scope could cut infection risk in ERCP
Knowledge-focused CompletedThis study tested a new single-use duodenoscope (aScope) in 59 patients at high risk of infection after ERCP, a procedure to treat bile duct problems. The goal was to see if the scope works well and to gather information on costs and complications. The results could help decide i…
Sponsor: Nottingham University Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC